Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Activated Cdc42-associated kinase (ACK), also known as ACK1 or TNK2, is a non-receptor tyrosine kinase that acts as an effector for the small GTPase Cdc42. It plays a significant role in transducing extracellular signals to cytosolic and nuclear effectors, impacting various cellular processes such as cell spreading, migration, survival, growth, and proliferation. ACK's dysregulation is implicated in various cancers, making it a potential therapeutic target.
Tyrosine kinase inhibition (potential)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Activated Cdc42-associated kinase (None).